Vitrolife faces a tough start in 2025, and we expect this to continue during H1 2025. In short, Vitrolife is stepping up its investments in commercial capacity and sales during a period of softer organic growth. In Q1, the softer areas are the APAC regions and technologies, apart from pressure in OPEX and operating cash flow.
LÄS MER
